2018
DOI: 10.2217/fon-2018-0006
|View full text |Cite
|
Sign up to set email alerts
|

An Overview of Meningiomas

Abstract: Meningiomas are the most common primary intracranial tumor. Important advances are occurring in meningioma research. These are expected to accelerate, potentially leading to impactful changes on the management of meningiomas in the near and medium term. This review will cover the histo- and molecular pathology of meningiomas, including recent 2016 updates to the WHO classification of CNS tumors. We will discuss clinical and radiographic presentation and therapeutic management. Surgery and radiotherapy, the two… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
304
1
44

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 375 publications
(441 citation statements)
references
References 89 publications
4
304
1
44
Order By: Relevance
“…Meningiomas are slow-growing, well-circumscribed tumors arising from the arachnoid cap cells of the dura mater. Most meningiomas are benign, which corresponds to the WHO grade I, and AM (WHO grade II) are reported in 5-7% of all cases (3,4). In the present study, we first compared some clinical characteristics between AM and BM patients.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Meningiomas are slow-growing, well-circumscribed tumors arising from the arachnoid cap cells of the dura mater. Most meningiomas are benign, which corresponds to the WHO grade I, and AM (WHO grade II) are reported in 5-7% of all cases (3,4). In the present study, we first compared some clinical characteristics between AM and BM patients.…”
Section: Discussionmentioning
confidence: 99%
“…In the present study, the overall recurrence rate was 40% within a median of 34 months; 60% of AM patients received complete resection and the recurrence rate was 11.1% in patients receiving complete resection. Currently, the recurrence rate varies among available studies, which might be partially related to the definition of recurrence, surgical methods and therapeutic strategies (3).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The first genetic alteration observed in meningiomas was monosomy of chromosome 22 or deletion of 22q; the key gene involved, NF2 is the gene involved in the genesis of the type-2 neurofibromatosis, and is located on 22q12, encoding the tumor suppressor merlin [97,98]. Interestingly, genetic abnormalities in meningiomas are different in relation to the location and the type of the lesion: in fact, SMO and AKT1-MTOR mutations are quite common in non-NF2, genomically stable meningiomas of the skull base.…”
Section: Meningiomamentioning
confidence: 99%
“…On the other hand, meningiomas with NF2 inactivation are genomically less stable and localize to the brain hemispheres. Moreover, mutations of NF2 are most frequent in fibroblastic/transitional meningiomas, KLF4 and TRAF7 in secretory meningiomas, and AKT1 mutations in grade I meningothelial meningiomas of the skull base and spine [97]. 80% of patients with recurrent chordoid meningiomas have complete deletions on all four chromosomal loci 22q, 18p, 14q, and 1p [99,100].…”
Section: Meningiomamentioning
confidence: 99%